ArticleExpert review of obstetrics & gynecology2012
Modulating the tumor immune microenvironment as an ovarian cancer treatment strategy.
Article in Expert review of obstetrics & gynecology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Article
- Cytoplasmic p53 aggregates accumulated in p53-mutated cancer correlate with poor prognosis.PNAS nexus · 2022Article
- Prognostic Value and Therapeutic Potential of CBX Family Members in Ovarian Cancer.Frontiers in cell and developmental biology · 2022Article
- Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment.International journal of molecular sciences · 2021Review
- Induction of antitumor immunity in mice by the combination of nanoparticle-based photothermolysis and anti-PD-1 checkpoint inhibition.Nanomedicine : nanotechnology, biology, and medicine · 2020Article
- Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy.Frontiers in cell and developmental biology · 2020Review
- The latest animal models of ovarian cancer for novel drug discovery.Expert opinion on drug discovery · 2018Review
- VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
- Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103(+) dendritic cells in late-stage ovarian cancer.Oncoimmunology · 2016Article
- M-Trap: Exosome-Based Capture of Tumor Cells as a New Technology in Peritoneal Metastasis.Journal of the National Cancer Institute · 2015Article
- New ways to successfully target tumor vasculature in ovarian cancer.Current opinion in obstetrics & gynecology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
After more than 30 years of iterations of surgical debulking plus chemotherapy, the need for complementary ovarian cancer treatments has become clear. In the ovarian cancer microenvironment, myeloid immunosuppressive leukocytes, lymphocytes, fibroblasts and endothelial cells, as well as their secreted products, surface molecules and paracrine survival factors, all provide opportunities for novel interventions. The potential of targeting microenvironmental elements in ovarian cancer patients is underscored by recently successful anti-angiogenic therapies. The compartmentalized nature of ovarian cancer, its immunogenicity and its accessibility make it an ideal disease for targeting non-tumor host cells. This review discusses the 'state-of-the-art' of the field, with an emphasis on the potential of modulating the activity of abundant microenvironmental immune cells, which govern both angiogenesis and immunosuppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.